Today, June 25, 2025, the annual general meeting was held in AcouSort AB (publ). Below is a summary of the decisions that were made. All decisions were made with the required majority.

Profit allocation and decision on discharge from liability. 
The meeting approved the income statement and balance sheet for both the parent company and the group. The meeting decided to dispose of the company's results according to the board's proposal in the annual report. The meeting further decided that no dividend will be paid for the financial year 2024. In addition, the meeting decided to discharge the members of the board and the CEO for the financial year 2024. 

Determining the fees for the board and auditor 
The meeting resolved that the board of directors shall consist of five board members and no deputy board members and that fees shall be paid to the board with two increased base amounts totaling 120,000 SEK to the chairman of the board and with an increased base amount of 60,000 SEK each to the other board members. Furthermore, the meeting resolved that one auditor and no deputy auditor shall be appointed and that fees to the auditor shall be paid according to an approved invoice in accordance with customary billing standards. 

Election of the board and auditor 
The meeting resolved to re-elect Thomas Laurell, Stefan Scheding and Katherine Flagg as board members and to elect Stefan Blomsterberg and Per Sundkvist as new board members. The meeting resolved that the board elect a chairman of the board. Furthermore, the meeting resolved that the company's auditor Öhrlings PricewaterhouseCoopers AB, with Mikael A Nilsson as auditor in charge, be re-elected until the end of the annual general meeting to be held next financial year. 

Decision on authorization for the board to issue shares, convertibles or warrants with preferential rights for the company's shareholders. 
The annual general meeting approved the board's proposal for authorization for the board to, on one or more occasions before the next annual general meeting, within the limits of the articles of association, only with preferential rights for the company's shareholders, decide on new issue of shares or issue of convertibles or warrants. Issuance must be possible against cash payment or set-off. 

Decision on authorization for the board to issue shares, convertibles or warrants without preferential rights for the company's shareholders. 
The annual general meeting approved the board's proposal to authorize the board to decide on a new issue of  shares or issue of convertibles or warrants on one or more occasions before the next annual general meeting, deviating from the shareholders' pre-emptive rights. The authorization is limited in such a way that the number of shares, after a fully subscribed new issue, full utilization of warrants or full conversion, does not increase by more than thirty-five (35) percent of the number of shares outstanding at the time of this meeting. In relation to the authorization for the board of directors to issue shares, convertibles and warrants without preferential rights for the company's shareholders, the board of directors undertook, following a request from a major shareholder, to limit the authorization so that the total number of shares that may be issued, or, in the case of an issue of convertibles or warrants, accrue after conversion or exercise, shall be limited to 15 percent of the number of shares outstanding at the time of the annual general meeting. 

Decision on incentive program
The Annual General Meeting approved the proposals to introduce an incentive program for employees and key personnel in the company, and to introduce an incentive program for board members in the company. In relation to the incentive program for employees, the Board of Directors, following a request from a major shareholder, undertook not to allocate more warrants to participants in category 1 (CEO) than the number of warrants offered to participants in category 2 (other management personnel), i.e. a maximum of 112,500 warrants. However, further allocation to participants in category 1 may be made if warrants remain after all other participants in the incentive program have been allocated as many warrants as they desired, including full possible over-allotment according to the resolution.

Miscellaneous 
The meeting decided to authorize the board, or whoever the board appoints, to carry out the minor adjustments that prove necessary when registering the decisions. 

Lund, June 2025
AcouSort AB (publ)
The Board

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is DNB Carnegie Investment Bank AB.

Attachments
Communiqué from the annual general meeting of AcouSort AB (publ)

Läs mer på MFN